These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27469406)

  • 1. Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs.
    Kern JC; Dooney D; Zhang R; Liang L; Brandish PE; Cheng M; Feng G; Beck A; Bresson D; Firdos J; Gately D; Knudsen N; Manibusan A; Sun Y; Garbaccio RM
    Bioconjug Chem; 2016 Sep; 27(9):2081-8. PubMed ID: 27469406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates.
    Kern JC; Cancilla M; Dooney D; Kwasnjuk K; Zhang R; Beaumont M; Figueroa I; Hsieh S; Liang L; Tomazela D; Zhang J; Brandish PE; Palmieri A; Stivers P; Cheng M; Feng G; Geda P; Shah S; Beck A; Bresson D; Firdos J; Gately D; Knudsen N; Manibusan A; Schultz PG; Sun Y; Garbaccio RM
    J Am Chem Soc; 2016 Feb; 138(4):1430-45. PubMed ID: 26745435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity.
    Wei B; Gunzner-Toste J; Yao H; Wang T; Wang J; Xu Z; Chen J; Wai J; Nonomiya J; Tsai SP; Chuh J; Kozak KR; Liu Y; Yu SF; Lau J; Li G; Phillips GD; Leipold D; Kamath A; Su D; Xu K; Eigenbrot C; Steinbacher S; Ohri R; Raab H; Staben LR; Zhao G; Flygare JA; Pillow TH; Verma V; Masterson LA; Howard PW; Safina B
    J Med Chem; 2018 Feb; 61(3):989-1000. PubMed ID: 29227683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cleavable linkers in antibody-drug conjugates.
    Bargh JD; Isidro-Llobet A; Parker JS; Spring DR
    Chem Soc Rev; 2019 Aug; 48(16):4361-4374. PubMed ID: 31294429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Conjugated Payload Measurement Using Enzymatic Release of Antibody-Drug Conjugate with Cleavable Linker.
    Rago B; Tumey LN; Wei C; Barletta F; Clark T; Hansel S; Han X
    Bioconjug Chem; 2017 Feb; 28(2):620-626. PubMed ID: 28140559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
    Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N
    Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers.
    Gray ME; Zielinski KM; Xu F; Elder KK; McKay SJ; Ojo VT; Benjamin SR; Yaseen AA; Brooks TA; Tumey LN
    Xenobiotica; 2024 Aug; 54(8):458-468. PubMed ID: 38738708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers.
    Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R
    Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid, High-Yielding Solid-Phase Synthesis of Cathepsin-B Cleavable Linkers for Targeted Cancer Therapeutics.
    Pryyma A; Gunasekera S; Lewin J; Perrin DM
    Bioconjug Chem; 2020 Dec; 31(12):2685-2690. PubMed ID: 33274932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of Antibody-Drug Conjugate Released Payload Species Using Directed in Vitro Assays and Mass Spectrometric Interrogation.
    Bessire AJ; Ballard TE; Charati M; Cohen J; Green M; Lam MH; Loganzo F; Nolting B; Pierce B; Puthenveetil S; Roberts L; Schildknegt K; Subramanyam C
    Bioconjug Chem; 2016 Jul; 27(7):1645-54. PubMed ID: 27206324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers.
    Jin C; Ei-Sagheer AH; Li S; Vallis KA; Tan W; Brown T
    Angew Chem Int Ed Engl; 2022 Mar; 61(13):e202114016. PubMed ID: 34953094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of attachment site on stability of cleavable antibody drug conjugates.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers.
    Miller JT; Vitro CN; Fang S; Benjamin SR; Tumey LN
    Bioconjug Chem; 2021 Apr; 32(4):842-858. PubMed ID: 33788548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody drug conjugates beyond cytotoxic payloads.
    Hobson AD
    Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late-Stage Desulfurization Enables Rapid and Efficient Solid-Phase Synthesis of Cathepsin-Cleavable Linkers for Antibody-Drug Conjugates.
    Ahangarpour M; Brimble MA; Kavianinia I
    Bioconjug Chem; 2024 Jul; 35(7):1007-1014. PubMed ID: 38874557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
    Balamkundu S; Liu CF
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
    Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
    Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Novel Glucocorticoids for Use in Antibody-Drug Conjugates for the Treatment of Inflammatory Diseases.
    Han A; Olsen O; D'Souza C; Shan J; Zhao F; Yanolatos J; Hovhannisyan Z; Haxhinasto S; Delfino F; Olson W
    J Med Chem; 2021 Aug; 64(16):11958-11971. PubMed ID: 34378927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.